KTTAW · Pasithea Therapeutics Corp.

$0.01 At close · Aug 18

Market Cap

$15.97M

33.41M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Tiago Reis Marques	Chief Executive Officer	$533,610	$493,150	—	$277,258	—	$23,500	$1,327,518
Daniel Schneiderman	Chief Financial Officer	$386,984	$306,400	—	$178,303	—	$23,500	$895,187
Graeme Currie	—	—	—	—	—	—	—	—

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Tiago Reis Marques	Chief Executive Officer	$450,000	—	$22,241	$167,818	—	—	$640,059
Chief Development	Officer	$386,535	—	—	$48,276	—	—	$434,811
Daniel Schneiderman	Chief Financial Officer	$330,000	—	—	$100,223	—	—	$430,223

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Tiago Reis Marques	Chief Executive Officer	$450,000	$30,000	$57,347	—	—	—	$537,347
Graeme Currie	Chief Development Officer	$330,647	$15,970	—	$98,247	—	—	$444,864
Daniel Schneiderman	Chief Financial Officer	$330,000	$15,939	—	—	—	—	$345,939

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Tiago Reis Marques	Chief Executive Officer	$450,000	$89,250	—	—	—	—	$539,250
Daniel Schneiderman	Chief Financial Officer	$135,205	$57,500	—	$174,498	—	—	$367,203
Graeme Currie	Chief Development Officer	$143,870	$55,000	—	—	—	—	$198,870
Stanley M. Gloss	Former Chief Financial Officer	$60,000	—	—	—	—	—	$60,000

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Tiago Reis Marques	Chief Executive Officer	$243,750	—	$288,000	$140,141	—	—	$671,891
Stanley M. Gloss	Former Chief Financial Officer	$67,500	—	$60,000	$284,665	—	—	$412,165
Daniel Schneiderman	Chief Financial Officer	—	—	—	—	—	—	—

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Stanley M. Gloss	Chief Financial Officer	—	—	—	—	—	—	—
Dr. Tiago Reis Marques	Chief Executive Officer	—	—	—	—	—	—	—

Executive changes

Person	Role	Change	Effective	Filed
Kartik Krishnan, M.D., Ph.D.	Chief Medical Officer	Appointed	2026-05-01	2026-05-04
Simon Dumesnil	Class II director	Appointed	2025-09-03	2025-09-03
Alfred Novak	Class II director	Appointed	2025-09-03	2025-09-03
Dr. Emer Leahy	Director	Appointed	2023-12-19	2023-12-19
Simon Dumesnil	Director	Appointed	2023-12-19	2023-12-19
Alfred Novak	Director	Appointed	2023-12-19	2023-12-19
Prof. Lawrence Steinman	Director	Appointed	2023-12-19	2023-12-19
Dr. Tiago Reis Marques	Director	Appointed	2023-12-19	2023-12-19
Daniel Schneiderman	Chief Financial Officer	Appointed	2022-10-11	2022-10-12
Alfred J. Novak	the Board and to its audit committee	Appointed	2022-09-14	2022-09-20
Dr. Lawrence Steinman	Board's audit committee	Resigned	2022-09-14	2022-09-20
Dr. Yassine Bendiabdallah	board of directors	Resigned	2022-09-14	2022-09-20

Key facts CIK 1841330 CUSIP 70261F202 13F (30d) 33 filings 32 filers Visit website Investor relations